CD8 T cells and E-cadherin in host responses against oropharyngeal candidiasis

Oral Diseases

Volumn 18, Issue 2, 2012, Pages 153-161

  Quimby, K ^a,b   Lilly, E A ^a,b   Zacharek, M ^c   McNulty, K ^a,b   Leigh, J E ^b   Vazquez, J E ^d   Fidel, P L ^a,b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d Henry Ford Health System Division of Infectious Diseases   (United States)

Author keywords

E cadherin; HIV; Oropharyngeal candidiasis

Indexed keywords

UVOMORULIN;

ADULT; ARTICLE; CANDIDA; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; FEMALE; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE RESPONSE; LONGITUDINAL STUDY; MALE; NONHUMAN; OROPHARYNX CANDIDIASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84855957132     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2011.01856.x     Document Type: Article

References (32)

1. Borg-von Zepelin M, Meyer I, Thomssen R et al (1999). HIV-Protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases. J Invest Dermatol 113: 747-751.
2. Calderone RA, Fonzi WA (2001). Virulence factors of Candida albicans. Trends Microbiol 9: 327-335.
3. Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R (1999). In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 180: 448-453.
4. Clift RA (1984). Candidiasis in the transplant patient. Am J Med 77(Suppl. 4D): 34-38.
5. Conti HR, Shen F, Nayyar N et al (2009). Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 206: 299-311.
6. Dodd CL, Greenspan D, Katz MH, Westenhouse JL, Feigal DW, Greenspan JS (1991). Oral candidiasis in HIV infection: pseudomembranous and erythematous candidiasis show similar rates of progression to AIDS. AIDS 5: 1339-1343.
7. Fichtenbaum CJ, Powderly W (1998). Refratory mucosal Candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis 26: 556-565.
8. Fisher-Hoch SP, Hutwagner L (1995). Opportunistic candidiasis: an epidemic of the 1980s. Clin Infect Dis 21: 897-904.
9. Frank CF, Hostetter MK (2007). Cleavage of E-cadherin: a mechanism for disruption of the intestinal epithelial barrier by Candida albicans. Transl Res 149: 211-222.
10. Greenspan JS, Barr CE, Sciubba JJ, Winkler JR (1992). Oral manifestations of HIV infection: definitions, diagnostic criteria and principles of therapy. Oral Surg Oral Med Oral Pathol 73: 142-144.
11. Gruber A, Speth C, Lukasser-Vogl E et al (1999). Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Immunopharmacology 41: 227-234.
12. Hogg N, Berlin C (1995). Structure and function of adhesion receptors in leukocyte trafficking. Immunol Today 16: 327-330.
13. Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH (1984). Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med 311: 354-357.
14. Knight L, Fletcher J (1971). Growth of Candida albicans in saliva: stimulation by glucose associated with antibiotics, corticosteriods and diabetes mellitus. J Infect Dis 123: 371-377.
15. Korting HC, Schaller M, Eder G, Hamm G, Böhmer U, Hube B (1999). Effects of human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob Agents Chemother 43: 2038-2042.
16. Laskaris G, Hadjivassiliou M, Stratigos J (1992). Oral signs and symptoms in 160 Greek HIV-infected patients. J Oral Pathol 21: 120-123.
17. Leigh JE, Steele C, Wormley FL Jr et al (1998). Th1/Th2 cytokine expression in saliva of HIV-positive and HIV-negative individuals: A pilot study in HIV-positive individuals with oropharyngeal candidiasis. J Acq Immun Defic Syndr Human Retrovirol 19: 373-380.
18. Leigh JE, Barousse M, Swoboda RK et al (2001). Candida-specific systemic cell-mediated immune reactivities in HIV-infected persons with and without mucosal candidiaisis. J Infect Dis 183: 277-285.
19. Macher AM (1988). The pathology of AIDS. Pub Health Rep 103: 246-254.
20. Matsuzaki G, Umemura M (2007). Interleukin-17 as an effector molecule of innate and acquired immunity against infections. Microbiol Immunol 51: 1139-1147.
21. McNulty KM, Plianrungsi J, Leigh JE, Mercante DE, Fidel PL (2005). Characterization of the CD8+ T-cells and microenvironment in oral lesions of HIV-infected persons with oropharyngeal candidiasis. Infect Immunol 73: 3659-3667.
22. Myers TA, Leigh JE, Arribas A et al (2003). Immunohistochemical evaluation of T cells in oral lesions from human immunodeficiency virus-positive persons with oropharyngeal candidiasis. Infect Immunol 71: 956-963.
23. Odds FC (1988). Chronic mucocutaneous candidiosis. In: Candida and candidosis. Baltimore, MD: University Park Press, pp. 104-110.
24. Palella FJ Jr, Delaney KM, Moorman AC et al (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860.
25. Reichart PA, Samaranayake LP, Philipsen HP (2000). Pathology and clinical correlates in oral candidiasis and its variants: a review. Oral Dis 6: 85-91.
26. Romani L, Mocci S, Bietta C, Lanfaloni L, Puccetti P, Bistoni F (1991). Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance. Infect Immunol 59: 4647-4654.
27. Schaller M, Korting HC, Schäfer W, Bastert J, Chen W, Hube B (1999). Secreted aspartic proteinase (Sap) activity contributes to tissue damage in a model of human oral candidosis. Mol Microbiol 34: 169-180.
28. Slavinsky J III, Myers T, Swoboda RK, Leigh JE, Hager S, Fidel PL Jr (2002). Th1/Th2 cytokine profiles in saliva of HIV-positive smokers with oropharyngeal candidiasis. Oral Microbiol Immunol 17: 38-43.
29. Steele C, Leigh JE, Swoboda RK, Fidel PL Jr (2000). Growth inhibition of Candida by human oral epithelial cells. J Infect Dis 182: 1479-1485.
30. Villar CC, Kashleva H, Nobile CJ, Mitchell AP, Dongari-Bagtzoglou A (2007). Mucosal tissue invasion by Candida albicans is associated with E-cadherin degradation, mediated by transcription factor Rim101p and Protease Sap5p. Infect Immunol 75: 2126-2135.
31. Zelante T, De Luca A, Bonifazi P et al (2007). IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 37: 2680-2682.
32. Zelante T, De Luca A, D'Angelo C, Moretti S, Romani L (2009). IL-17/Th17 in antifunal immunity: what's new? Eur J Immunol 39: 645-648.